Otsuka's monoclonal antibody Voyxact has received FDA approval for the treatment of primary IgA nephropathy (IgAN) in people who are at risk of the illness progressing. Following Phase 3 data showing notable and long-lasting decreases in proteinuria, the permission was granted. Voyxact is given once every four weeks, and options for at-home administration are anticipated to increase therapy accessibility. Data on long-term renal outcomes are still being gathered.
Source Reference:
FDA Approval Announcement:
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-voyxact-iga-nephropathy
